Literature DB >> 15041798

Angiogenesis and the ET-1/ETA receptor system: immunohistochemical expression analysis in bone metastases from patients with different primary tumors.

M Medinger1, C P Adler, C Schmidt-Gersbach, J Soltau, A Droll, C Unger, J Drevs.   

Abstract

Angiogenesis is necessary for the growth of primary tumors and the formation of metastases. It is well known that vascular endothelial growth factor (VEGF) and its receptors play a major role in this process. To date, the formation of bone metastases has been poorly understood. Tumor cells must interact with the microenvironment of the bone and new blood vessels must spread. The ET/ET(A) (endothelin) receptor system seems to play an important role in this process. Specimens from metastatic bone lesions and non-malignant bone tissue were analyzed by histological and immunohistochemical staining. Sections were stained with antibodies against CD31, Flt-1, KDR, endothelin-1 (ET-1) and endothelin receptor A (ET(A)). Our studies show that there is an increased microvessel density (MVD) in metastatic bone lesions from different primary tumors in contrast to normal bone tissue. In nearly all tumor formations of the bone, ET-1 and its receptor ET(A) was found by immunohistochemistry. We also performed immunohistochemical staining for the VEGF-receptors Flt-1 and KDR. In conclusion, there is an increased vessel density in metastatic bone lesions in contrast to normal bone tissue. The ET/ET(A) system can be detected in nearly all bone specimens and is upregulated in metastatic bone lesions in contrast to healthy bone tissue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15041798     DOI: 10.1023/B:AGEN.0000021395.43438.44

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  6 in total

1.  Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis.

Authors:  Didier Dréau; Amel Karaa; Cathy Culberson; Heather Wyan; Iain H McKillop; Mark G Clemens
Journal:  Clin Exp Metastasis       Date:  2006-07-07       Impact factor: 5.150

2.  Updating advances on recombinant human endostatin combined with radiotherapy for non-small cell lung cancer with brain metastasis.

Authors:  Xiao-Dong Jiang; Yun Qiao
Journal:  Transl Lung Cancer Res       Date:  2012-03

3.  Effect of endothelin-1 in esophageal squamous cell carcinoma invasion and its correlation with cathepsin B.

Authors:  Wen-Jie Jiao; Jing Xu; Hao Pan; Tian-You Wang; Yi Shen
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

4.  Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility.

Authors:  Badan Sehrawat; Malinee Sridharan; Sunita Ghosh; Paula Robson; Carol E Cass; John R Mackey; Russell Greiner; Sambasivarao Damaraju
Journal:  Hum Genet       Date:  2011-03-19       Impact factor: 4.132

5.  Comparison of plasma endothelin levels between osteoporotic, osteopenic and normal subjects.

Authors:  Hasan Hilmi Muratli; Levent Celebi; Onur Hapa; Ali Biçimoğlu
Journal:  BMC Musculoskelet Disord       Date:  2005-09-20       Impact factor: 2.362

6.  Elevation of circulating big endothelin-1: an independent prognostic factor for tumor recurrence and survival in patients with esophageal squamous cell carcinoma.

Authors:  Wenjie Jiao; Jing Xu; Jinsheng Zheng; Yi Shen; Lesheng Lin; Jian Li
Journal:  BMC Cancer       Date:  2008-11-15       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.